- Home
- SLGB vs ADAG Comparison
SLGB vs ADAG Comparison
Compare SLGB & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SLGB | ADAG |
|---|---|---|
| Founded | 2017 | 2011 |
| Country | Hong Kong | China |
| Employees | N/A | N/A |
| Industry | Integrated Freight & Logistics | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 75.4M | 90.5M |
| IPO Year | 2025 | 2021 |
Fundamental Metrics
Financial Performance| Metric | SLGB | ADAG |
|---|---|---|
| Price | $1.31 | $2.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $8.00 |
| AVG Volume (30 Days) | ★ 9.0M | 249.8K |
| Earning Date | 02-24-2026 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $99,438,843.00 | $103,204.00 |
| Revenue This Year | N/A | $3,688.61 |
| Revenue Next Year | N/A | $17.39 |
| P/E Ratio | $29.79 | ★ N/A |
| Revenue Growth | ★ 7.29 | N/A |
| 52 Week Low | $0.92 | $1.30 |
| 52 Week High | $6.08 | $3.19 |
Technical Indicators
Market Signals| Indicator | SLGB | ADAG |
|---|---|---|
| Relative Strength Index (RSI) | 43.92 | 58.72 |
| Support Level | $1.46 | $2.41 |
| Resistance Level | $1.72 | $3.19 |
| Average True Range (ATR) | 0.72 | 0.43 |
| MACD | -0.08 | 0.01 |
| Stochastic Oscillator | 5.11 | 64.91 |
Price Performance
Historical ComparisonAbout SLGB Smart Logistics Global Limited Ordinary Shares
Smart Logistics Global Ltd is a contract logistics solution provider in the PRC focusing on industrial raw materials line-haul transportation business. the group focuses on the logistics digital ecosystem through innovation, digital analytics, and infrastructure establishment.
About ADAG Adagene Inc.
Adagene Inc is a platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development, and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity, as highlighted by the company's immunotherapy pipeline.